Form 4 for SPRY ARS Pharmaceuticals, Inc.
Accepted 2025-11-14 00:00:00 ET · period of report 2025-11-13 · accession 0001380762-25-000005 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-11-14 | 2025-11-13 | SPRY | Dorsey Brian | COO | M - OptEx | $0.64 | +21.8K | 32.6K | +202% | +$14.0K |
| D | 2025-11-14 | 2025-11-13 | SPRY | Dorsey Brian | COO | S - Sale+OE | $8.71 | -21.8K | 10.8K | -67% | -$190.1K |
| D | 2025-11-14 | 2025-11-13 | SPRY | Dorsey Brian | COO | M - OptEx | $0.00 | -21.8K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-11-13 | M | A | 21,828 | $0.64 | 32,617 | D | — | — | (F1) Includes 1,628 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan ("ESPP") on December 31, 2024 and 3,137 shares acquired under the ESPP on June 30, 2025. |
| 2 | Common | Common Stock | 2025-11-13 | S | D | 21,828 | $8.71 | 10,789 | D | — | — | (F2) The weighted average sale price for the transaction report was $8.7067, and the range of prices was between $8.63 and $8.835. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| 3 | Derivative | Stock Option (Right to Buy) | 2025-11-13 | M | D | 21,828 | $0.00 | 0 | D | $0.64 · — to 2028-11-28 | 21,828 Common Stock | (F3) Immediately exercisable. |